Share Price, page-10844

I agree. I don't know what the objectives are either, but it won't matter when sustained buying interest returns. We know that Acadia will report earnings next month, and we will also have our own quarterly update. I shouldn't be feeling so cynical, but I am questioning the impact of a positive Angelman read out. It is certain we will have our share price hammered on a weak or mediocre result. The thing is, though, 3 positive read outs across 3 separate indications is such a strong marker of success going forward. One, or even two trials with a lower number of patients and no placebo raises questions about whether the data is as strong as suggested, when there's 3 or more it's very hard to argue against the probability of replicating similar data in a Phase 3.

I really think Phelan McDermid Syndrome is the most valuable indication of right now. Strongest data (so far), large patient population, competitive advantage (in terms of competitors with drugs in development). I think if we could do well in any of the 4 read outs, it would be this indication and we've already ticked that off, convincingly.